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ABSTRACT 
Background and aims. The present study aimed to assess the frequency of spasticity in a single-centre cohort of stroke patients 
in a one-year follow-up, its predictors, and its impact on the activities of daily living (ADL) and health-related quality of life (HRQoL).
Material and methods. A group of 121 consecutive patients with hemiparesis (aged 73 ± 11 years) was selected for further 
observation, out of 381 Stroke Department patients during one year. At three follow-up assessments three, six and 12 months 
after stroke, muscle tone and muscle weakness were rated using Modified Ashworth Scale (MAS) and Medical Research Council 
(MRC); Activities of Daily Living (ADL) and Health Related Quality of Life (HRQoL) were evaluated using the Barthel Index (BI), 
Modified Rankin Scale (mRS) and an SF-36 questionnaire.
Results. Fifty five of 121 (45%) patients after three months had developed spasticity (MAS ≥ 1), and in 19 of the 121 (15%) this 
spasticity was severe. After one year, 33/94 (35%) patients showed spasticity, and in 19/94 (20%) it was severe. Baseline muscle 
weakness (MRC), stroke severity as measured by the National Institutes of Health Stroke Scale (NIHSS), and greater disability 
(BI), were the most significant predictors of persistent post-stroke spasticity. Patients with spasticity had worse HRQoL in terms 
of their physical functioning, role limitations, physical pain, and vitality.
Conclusion. Spasticity, which affects a significant proportion of stroke survivors, was present in 35% of our patients at 12 
months after stroke. It has a major impact on both ADL and HRQoL. Severe disability and muscle weakness are the most impor-
tant predictors of persistent post-stroke spasticity.
Key words: spasticity, stroke, epidemiology, quality of life, predictors, hemiplegia
(Neurol Neurochir Pol 2019; 53 (6): 449–457)
Introduction
Stroke is a leading cause of disability among adults. Upper 
motor neuron syndrome with accompanying spasticity is its 
major clinical presentation [1, 2]. Spasticity is not only one of 
the major factors contributing to the handicap, but also one 
that can be treated pharmacologically [3]. According to Euro-
pean and Asian studies, the prevalence of post-stroke spasticity 
ranges from 7% to 38% in up to 18-month observations [4, 
5]. In two German and Swedish studies in patients with initial 
limb paresis after stroke, the prevalence of spasticity was 42% 
and 46% at six and 12 months respectively [6, 7]. The literature 
focusing on the impact of spasticity on the activities of daily 
living (ADL) and health-related quality of life (HRQoL) is 
limited [8]. The present study aimed to indicate prospectively 
the frequency of spasticity, its impact on ADL and HRQoL, and 
to identify predictors of persistent spasticity in a single-centre 
cohort of stroke patients.
Subjects and methods
Subjects
All patients admitted to the Stroke Unit at the Neurology 
Department were consecutively recruited over a 12-month 
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period. This Neurology Department is exclusively respon-
sible for the neurological care of a  region with around 
200,000 inhabitants, and all stroke patients without any 
selection were admitted. All adult stroke patients with 
limb paresis at discharge were invited to participate in the 
study. The presence of other neurological diseases that af-
fect muscle tone and treatment with botulinum toxin were 
the only two exclusion criteria. Medical records of a total 
of 381 patients were screened, and of these 121 patients 
were selected and assessed three months after stroke onset. 
Of the 121 study participants, 99 were reassessed at six 
months and 94 at 12 months after stroke (see Fig.1). The 
patients’ age averaged 73.74 years (± 11.45; range 23–97). 
Females were more prevalent, comprising 66 (54.5%). Our 
selected group did not differ in terms of age and sex from 
the remaining stroke patients of the entire cohort (n = 381). 
Clinical characteristics of the cohort included in the study 
are set out in Table 1. 
Muscle tone assessment
Spasticity was assessed with the use of the Modified 
Ashworth Scale (MAS) [9], grading the resistance of a relaxed 
limb to rapid passive stretching over six stages. In the present 
study, arm adductors, elbow flexors/extensors, wrist flexors/
extensors, and finger flexors were examined with the patient 
in a sitting position. In the lower limbs, hip adductors, knee 
flexors/extensors, and plantar flexors/extensors were tested 
in patients in a  supine position. The MAS is considered 
to be fairly reliable [10] and correlates to more objective 
electrophysiological tests [11]. Three degrees of spasticity 
in any of the muscle groups were defined: any (MAS ≥ 1), 
moderate (MAS ≥ 2), and severe (MAS ≥ 3). All assessments 
were performed by the same physician (M.S.).
Stroke severity and motor assessments
Initially in the acute phase of stroke, patients were assessed 
with the National Institutes of Health Stroke Scale (NIHSS), 
which is a 46-point scale. This is considered reliable and valid 
as well as quick and easy to use [12]. At discharge from the 
Neurology department, and three, six and 12 months after 
stroke, muscle strength was assessed by Medical Research 
Council (MRC) (grades 0 to 5) for all muscle groups that were 
also tested for muscle tone [13].
Activities of daily living and quality of life
Disability related to activity performance and participation 
was assessed with the use of the Modified Rankin Scale (mRS) 
and the Barthel Index (BI) which are considered to be reliable, 
valid and sensitive [14, 15]. HRQoL was assessed by the Short 
Form 36 Health Survey Questionnaire (SF-36) v.2 [16], which 
consists of 36 items grouped into the following eight health 
scales: physical functioning, role limitations due to physical 
problems, physical pain, general health perceptions, vitality, 
social functioning, role limitations due to emotional problems, 
and mental health. This is considered to be a reliable and valid 
measure of physical-health-related  and mental-health-related 
quality of life after stroke [17]. Eighty patients were able to 
complete the SF-36 form. 
Patients admitted to the Neurology Dept. 
with ischaemic and haemorrhagic stroke 
in one year (n = 381)
Patients included in the study 
3 months after stroke (n = 121)
Patients included in the study 
6 months after stroke (n = 99) 
Patients included in the study
12 months after stroke (n = 94) 
No limb paresis (MRC = 5) n = 151 
Death n = 63 
Loss of contact n = 39 
Unwilling to participate n = 7 
(n = 260) 
Death n = 13 
Loss of contact n = 4 
Unwilling to participate n = 4 
Another stroke n = 1 
(n = 22) 
Death n = 3 
Loss of contact n = 1 
Unwilling to participate n = 1 
(n = 5) 
Figure 1. Detailed recruitment schedule
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Table 1. Clinical and demographic characteristics of study participants
Variable Number Percentage (%) Variable Mean Median SD Min.–Max.
Sex: Age 73.74 75.00 11.45 23–97
Female 66 54.5 NIHSS admisson 9.79 8.00 6.90 1–33
Male 55 45.5 NIHSS discharge 6.63 4.00 6.27 0–32
Stroke aetiology: BI discharge 54.95 65.00 39.03 0–100
Ischaemic 112 92.6 mRS discharge 3.07 3.00 1.4 0–5
Haemorrhagic 9 7.4
Localisation:
Right hemisphere 59 48.8




History of stroke 23 19.2
Hypertension 100 83
Atrial fibrillation 39 32.1
Dyslipidemia 55 45.5
Diabetes 33 27.1
Coronary disease 39 32.1
Thrombolytic therapy 7 5.7
Carotid arterty stenosis 23 19.1
Smoking 14 11.5
Alcohol abuse 3 2.5
NIHSS — National Institutes of Health Stroke Scale, BI — Barthel Index, mRS — Modified Rankin Scale
Predictors of spasticity
Data obtained during hospitalisation such as muscle we-
akness (MRC), disability (mRS, BI), stroke severity (NIHSS), 
aetiology and location of stroke, aphasia, dysarthria, presence 
of hypertension, atrial fibrillation, dyslipidemia, diabetes, 
coronary heart disease, previous stroke, history of smoking, 
alcohol abuse, and intravenous thrombolytic therapy were 
analysed to determine the risk factors for spasticity.
Statistical analysis
The Shapiro-Wilk test and Brown-Forsythe tests were used 
to test the normality of distribution and the homogeneity of 
variance respectively. Intergroup differences were tested with 
thec² test for categorical variables and Mann-Whitney U tests 
for continuous variables. The associations between MAS and 
the MRC, BI, NIHSS, mRS were analysed with the use of Spear-
man rank-order correlation coefficient. Multivariate backward 
stepwise logistic regression analysis was used to predict the 
presence of (a) any spasticity, (b) moderate spasticity and (c) 
severe spasticity at three, six and 12 months post-stroke either 
in any of the limbs or separately for the upper limbs and the 
lower limbs. A two-stage approach was used to build regression 
models. Initially, univariate regression analyses were used 
to screen for variables likely to be associated with spasticity 
at each time point (p < 0.10). Variables such as age, sex, left 
/ right sided weakness, thrombolysis, history of previous 
stroke, NIHSS score at discharge, BI, MRC total score (global 
or for upper / lower limbs respectively) at the first and at the 
second assessment were considered as possible predictors of 
spasticity. Also, correlation analysis was performed, as in each 
of the analyses the correlation coefficients between MRC total 
score at baseline and at three months were higher than 0.80; 
only baseline score (easier to measure from the clinical point 
of view) was considered for further analyses. Then, possible 
interactions among the selected variables were identified. 
Finally, the variables identified in univariate analyses and 
their interactions were entered into a multivariate backward 
stepwise regression model.
The results are presented with nonstandardised coeffi-
cients, p values, and odds ratios with 95% confidence intervals 
(95% CIs). Significance level was set at p < 0.05, unless specified 
otherwise (in the case of exploratory analyses). Nagelkerke 
R2 was used as a measure of goodness of fit. All statistical 
analyses were performed using Microsoft Excel 2010, IBM 
SPSS statistics 23.0, R-project ver. 3.0.2 and STATISTICA 
Statsoft Poland v12, including Plus Set 3.0.
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The prevalence of different degrees of spasticity is set out in 
Table 2. Generally, frequency of spasticity decreased between 
three and 12 months post stroke from 45% to 35% in the upper 
limbs (UL) and from 32% to 27% in the lower limbs (LL). 
Distribution of spasticity
In the UL, increased muscle tone was observed most 
frequently in elbow flexors/extensors, followed by shoulder 
adductors, wrist flexors/extensors, and finally in fingers in the 
12-month observation. The distribution was variable over time, 
and distal spasticity (fingers, wrist) was more pronounced 
after 12 months. Spasticity did not differ between proximal 
and distal muscle groups in the LL, but over time more severe 
spasticity in plantar flexors was observed. The distribution of 
different muscle groups within the UL and the LL is presented 
in Figure 2. 
Impact of spasticity on the activities of daily 
living and health related quality of life
Spastic patients were more disabled as measured by mRS 
and BI, (Tab. 3) and these differences persisted over time. 
Table 2. Number of patients with spasticity in both upper and lower limbs
Months after stroke No. of patients Frequency N (%)
MAS ≥ 1 MAS ≥ 2 MAS ≥ 3
3 121 55 (45) 45 (37) 19 (15)
6 99 41 (41) 35 (35) 23 (23)
12 94 33 (35) 29 (31) 19 (20)
Number of patients with spasticity in upper limbs
Months after stroke No. of patients Frequency N (%)
MAS ≥ 1 MAS ≥ 2 MAS ≥ 3
3 121 55 (45) 43 (35) 18 (15)
6 99 41 (41) 34 (34) 23 (23)
12 94 33 (35) 29 (31) 17 (18)
Number of patients with spasticity in lower limbs
Months after stroke No. of patients Frequency N (%)
MAS ≥ 1 MAS ≥ 2 MAS ≥ 3
3 121 39 (32) 31 (26) 14 (11)
6 99 31 (31) 24 (24) 12 (12)
12 94 25 (27) 18 (19) 14 (15)
MAS — Modified Ashworth Scale
Figure 2. Severity and distribution of spasticity in different muscle groups in upper and lower limbs after 12 months




















4 3 2 1,1+
MAS















4 3 2 1,1+
MAS








Michał Jakub Schinwelski et al., Prevalence and predictors of post-stroke spasticity




Patients with spasticity Patients without spasticity P-value
Mean Median Mean Median
3 3.2 3 2.27 2 0.0006
6 3.17 3 1.7 1 0.0000004




Patients with spasticity Patients without spasticity P-value
Mean Median Mean Median
3 60.27 80 70.08 92.05 0.023
6 61.71 80 85.09 100 0.00007
12 62.42 80 86.07 100 0.00001
Spasticity correlated strongly with the degree of muscle we-
akness (rho from -0.418 to -0.933, p < 0.001) and hence also 
correlated significantly with mRS (rho from 0.379 to 0.582, 
p < 0.001) and BI (rho from -0.279 to -0.482, p < 0.01) scores. 
In terms of HRQoL, those patients without spasticity were 
less impaired in terms of physical functioning, physical and 
emotional role limitations, physical pain, and vitality subsca-
les of the SF-36 scale (Fig. 3). Additionally, the presence and 
degree of spasticity significantly correlated with all mentioned 
SF-36 subscale scores (rho from -0.280 to -0.517, p < 0.05). 
Predictors of spasticity 12 months after stroke
In almost all of the models (apart from the one predicting 
LL spasticity at 12 months), MRC total score was a significant 
predictor of spasticity. In all models predicting spasticity 
at three months, and in the model predicting LL spasticity 
at 12 months, BI was also significant. Of note, NIHSS was 
a predictor only of LL spasticity, both at three and 12 months. 
Another significant predictor of spasticity was previous stroke 
history (for LL spasticity). In none of the analyses were age, 
sex, side of symptoms, or thrombolytic therapy identified as 
significant independent factors predicting spasticity. 
The results of multivariate logistic regression are set out 
in Table 4.
Discussion
This is the first East European prospective study on the 
prevalence of spasticity. Spasticity was present in 45%, 41% 
and 35% of initially paretic patients at three, six and 12 months 
after stroke respectively. The incidence of spasticity varies 
across the studies, with the lowest in Korean [5] and Swe-
dish studies [18–20] from 7% at 12 months (Korean), 18% 
after one week up to 21% at 18 months (Swedish), moderate 
(36–38%) in two British studies [21, 22] in 12-month obser-
vations, and the highest (42% and 46%) in a German study 
[6] and a recent Swedish study [7] after six and 12 months. 
The discrepancies between studies may result from different 
methods and definitions. The frequency of variously defined 
‘severe’ spasticity ranged from 6% in Lundström et al. [20], 
which defined severe spasticity as “spasticity having such an 
impact that intervention, e.g. intensive physiotherapy, orthoses 
or pharmacological treatment, should be offered” to 15%, 21%, 
and 29% with the definition of severe spasticity measured as 
MAS ≥ 3, Tone Assessment Scale (TAS) ≥ 2 or MAS ≥ 2 in 
studies by Urban et al. [6], Watkins et al. [21] and Opheim et 
al. [7]. A descriptive definition of spasticity without referring 
to cut-offs on clinimetric scales may lower the number of 
patients with spasticity. 
Contrary to previous reports, the prevalence of any 
spasticity (MAS ≥ 1) in our study decreased in 12 months of 
observation. This could be explained by a relatively small but 
noticeable drop-out rate throughout the study, and the transfer 
of patients with any spasticity (MAS ≥ 1) measured only in one 
joint into the group without spasticity. This transfer is possibly 
due to physiotherapy within the first year after stroke. A similar 
observation was found in Sommerfeld et al.’s [18] study, with 
a lower rate of spasticity after three months compared to the 
first weeks after stroke.
The established number of patients developing spasticity 
after three months seems the most valuable finding from the 
practical point of view. At this time point, the neural com-
ponent is gradually replaced by a biomechanical one, which 
means that rehabilitation and pharmacological therapy, e.g. 
with botulinum toxin injections, become less effective [23].
Our study design, with its recruitment of consecutive 
patients from one inpatient neurological centre, is similar 
to that of the majority of other studies [6, 7, 18–20] and 
makes it possible to assess the real prevalence of spasticity. 
Additionally, the assessment of muscle tone by the same 
physician throughout the study eliminated potential inter-
-rater variability.
In our study, 19% of patients had a history of previous 
stroke, while in a British study [21] such patients constituted 
34% of the study group. The inclusion of cases with a previous 
history of stroke was important because the number of such 
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patients being seen in stroke units is increasing, and a second 
stroke may increase the risk of spasticity and influence its fre-
quency [21]. Of note, in our cohort it was one of the significant 
spasticity risk factors for lower limb spasticity.
In our study, the frequency of spasticity was 10% higher 
in the UL than in the LL, which may result from the greater 
supraspinal control in UL [26]. Spasticity was most frequent in 
elbow flexors, arm adductors, and wrist and finger flexors, in 
that order. In the lower limbs, knee flexors and extensors were 
most commonly affected. The distribution of spasticity was 
rather stable, but the severity of spasticity increased distally 
in both extremities over time. These results confirm those of 
other studies [6, 27] that have found spasticity is common in 
the anti-gravity muscles, and significantly increases over time. 
This may be explained initially by neural changes, i.e. incre-
ased tonic stretch reflexes, followed later by intrinsic muscle 
changes. Additionally, more severe spasticity in distal parts 
of extremities could be associated with their larger cortical 
representations and long-lasting supraspinal mechanisms of 
spasticity evolution related to brain plasticity following limb 
disuse [28]. 
All of the cited studies [6, 7, 18–22] have found a rela-
tionship between spasticity and a worse functional outcome. 
ADL has been assessed using various methods (e.g. BI, mRS, 
Brigitta Lindmark, Nine Hole Peg Test, Rivermead Mobility 
Index, Get Up and Go test), but BI was the most frequently 
used outcome measure. Similarly, in our study significant 
associations between severity of spasticity and functioning as 
measured by BI and mRS were found. As in Swedish studies 
[18, 19] the strength of these associations increased during 
the 12-month observation. Considering that paresis is usually 
stable at 12 months, it is presumably spasticity that causes 
deterioration in functioning [29]. Thus, spasticity should be 
managed as early as possible.
Stroke survivors had a  lower QoL than age-matched 
controls in 7/8 domains (excluding pain) [19, 30]. However, 
Figure 3. Health-related quality of life in hemiparetic patients with and without spasticity according to eight domains of SF-36 scale
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as spasticity is the third greatest cause of chronic pain in pa-
tients after stroke [31], in our study pain was among five QoL 
domains that were more affected in individuals with spasticity 
compared to those without. The worse QoL scores in terms 
of physical functioning and role limitations due to physical 
problems are in accordance with previous reports regarding 
the impact of spasticity on ADL. These findings suggest that 
spasticity does have a major impact on HRQoL, as well as on 
ADL, in stroke patients. Of note, Elovic et al. showed that 
botulinum toxin injections can alleviate spasticity, improve 
QoL, and reduce disability [32].
Even though stroke characteristics such as age, sex, side 
of symptoms and co-morbidities were included into analysis, 
mulitivariate analysis did not show any predictors of spasti-
city except for NIHSS score and a previous stroke. In earlier 
studies, young age and haemorrhagic stroke were identified as 
risk factors [20], but in our cohort there were only 9/121 hae-
morrhagic stroke patients, and this was probably responsible 
for the lack of significance of this possible spasticity predictor.
Severity of spasticity and degree of limb paresis were 
strongly associated in our study, and this is in accordance with 
previous reports [6, 20]. 
BI at discharge was identified as a significant predictor of 
spasticity, which seems to be important due to the wide use of 
this scale. In a previous study, lower sensorimotor function as 
identified by the Fugl-Mayer-Upper Extremity-Assessment and 
Motricity Index predicted spasticity at three and 12 months 
after stroke [7, 33]. Identifying BI and NIHSS scores as pre-
dictors of spasticity seems more relevant to routine clinical 
practice. 
A relatively large cohort of stroke survivors with initial 
limb paresis, assessed prospectively by one physician so as to 
avoid inter-rater variability, is the major strength of our study. 
A deterioration in the HRQoL score in the spasticity group 
was also demonstrated, and this may explain why vigorous 
treatments are needed. 
However, our study design had several limitations. Be-
cause the first follow-up assessment was after three months, 
the precise time when spasticity could be noticed has not 
been established. Also, the influence of rehabilitation and of 
oral antispastic medication (the efficacy of the latter having 
been questioned), were not analysed. In future studies, more 
frequent follow-up muscle tone assessments during the first 
month after stroke may enable optimal timing of early botu-
linum toxin treatment combined with a specific rehabilitation 
programme [34]. 
Conclusions
Spasticity is a relatively frequent sequel of stroke, and has 
major impacts on daily functioning and quality of life. Pro-
nounced paresis, more severe disability, and stroke severity 
at baseline, are the most important predictors of developing 
spasticity in more than one third of patients.
Table 4. Predictors of post-stroke spasticity in any limb / upper limbs / lower limbs at three, six and 12 months: results of multivariate logistic regression 
analysis
Months after stroke Predictors of MAS ≥ 1 Unstandardised 
coefficient
P-value OR 95% CI Nagelkerke R2
Lower Upper
At 3 months BI 0.137 0.001 1.147 1.060 1.241 0.350
Total MRC at baseline * BI -0.005 0.000 0.995 0.992 0.998
At 3 months in the UL BI 0.136 0.003 1.146 1.049 1.252 0.378
Total UL MRC at baseline * BI -0.009 0.001 0.991 0.986 0.996
At 3 months in the LL Previous stroke history 0.684 0.018 5.051 1.322 19.303 0.562
BI 0.348 0.000 1.417 1.192 1.684
NIHSS -0.112 0.035 0.894 0.805 0.992
BI * age -0.003 0.000 0.997 0.995 0.998
BI * total LL MRC at baseline -0.006 0.000 0.994 0.991 0.997
At 6 months Total MRC at baseline -0.379 0.000 0.684 0.573 0.818 0.613
At 6 months in the UL Total UL MRC at baseline -0.537 0.000 0.584 0.442 0.773 0.592
At 6 months in the LL Total LL MRC at baseline -0.869 0.000 0.419 0.280 0.628 0.569
At 12 months Total MRC at baseline -0.300 0.000 0.741 0.647 0.847 0.577
At 12 months in the UL Total UL MRC at baseline -0.483 0.0000 0.617 0.484 0.787 0.597
At 12 months in the LL NIHSS 0.258 0.012 1.294 1.059 1.581 0.544
BI -0.030 0.016 0.971 0.948 0.995
BI * previous stroke history 0.025 0.024 1.025 1.003 1.048
UL — upper limbs, LL — lower limbs, MRC — Medical Research Council, BI — Barthel Index, NIHSS — National Institute of Health Stroke Scale, 
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